Despite the availability of HIV testing guidelines to facilitate prompt diagnosis, late HIV diagnosis remains high across Europe. The study synthesizes recent evidence on HIV testing strategies adopted in health care settings in the European Union/European Economic Area (EU/EEA).
Introduction
In 2017, 49% of people diagnosed with HIV infection were first identified at a late stage of infection (CD4 count < 350 cells/µL) in Europe [1] . Late diagnosis is associated with increased risk of morbidity and mortality [2, 3] as well as increased risk of onward transmission of HIV as a consequence of delayed initiation of treatment This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
[4]. The Joint United Nations Programme on HIV/AIDS (UNAIDS) set the global 90-90-90 target where 90% of all people with HIV infection should be diagnosed, 90% of those diagnosed should receive HIV treatment and 90% of those on treatment should have a suppressed viral load by 2020 [5] . HIV testing is therefore a vital first step in the HIV care continuum and in Europe it has historically been offered in traditional health care settings, such as sexual health clinics, antenatal services and voluntary counselling and testing sites. Testing guidance for sexually transmitted infection (STI)/genitourinary/dermatovenereology clinics exists at national, European and international levels promoting universal testing offer [6] [7] [8] [9] [10] . However, other health care settings that are nonspecialist for HIV and where patients are presenting for the management of other conditions present opportunities to increase HIV testing, thereby reducing undiagnosed infections. In 2016, an estimated 101 400 people were living with undiagnosed HIV infection in the European Union/ European Economic Area (EU/EEA), and, although this represents a decline in the number since 2012, it highlights the continued need for effective HIV testing programmes to improve HIV test coverage [11] .
The World Health Organization (WHO) consolidated guidelines on HIV testing services, recommending that HIV testing services should be integrated with other relevant clinical services such as those for tuberculosis (TB), maternal health, sexual and reproductive health and harm reduction programmes, especially as these services attract populations considered to be at higher risk for HIV infection [9] . The guidelines endorse the use of provider-initiated testing and counselling when the epidemic is generalized and the routine offer of testing for all clients in all health facilities (including primary care, inpatient and outpatient services and all services for key populations) is recommended as an effective way to identify people with HIV infection.
Although guidance is available from international organizations and national public health bodies to inform service provision for HIV testing [12] , health care providers within European countries need to be able to operationalize these into clinical practice so as to diagnose HIV infection at an earlier stage of infection. An evidence synthesis published in 2010 by the European Centre for Disease Prevention and Control (ECDC) showed that a number of strategies could reduce missed opportunities for HIV testing, including indicator condition (IC)-guided testing, which involves offering testing to all patients presenting to care with an AIDS-defining illness or with an HIV 'indicator' condition (IC) [8] . An HIV IC is a condition associated with an undiagnosed HIV prevalence of at least 1 per 1000 [13] . Other strategies were routine HIV testing implemented as part of routine care in health care settings and the use of rapid tests that offer immediate results.
A recent evaluation of the 2010 ECDC guidance found that, although the document was considered important for policy and guideline development, an update to the guidance was necessary to incorporate new approaches and technologies that have been adopted to increase testing offer and coverage in recent years [14] . The purpose of this paper is to present the recent body of evidence on HIV testing strategies employed in health care settings in Europe. Additionally, the paper reviews the evidence on testing provision strategies that increase HIV testing coverage and on the feasibility and acceptability of HIV testing strategies. The systematic review described here was conducted as part of a wider review of the evidence on HIV testing in the EU/EEA and barriers to testing to update the 2010 ECDC HIV testing guidance.
Methods
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for the reporting of systematic reviews [15] . A full description of the methodology is described elsewhere [16] . Briefly, five electronic databases (OVID Medline, Embase, PsycINFO, Scopus and the Cochrane Library of Systematic Reviews) (January 2010 to March 2017) and the proceedings of six conferences (2014-2017) were searched using key search terms covering concepts including 'HIV', 'HIV testing' and 'Europe' (Tables S1-S5 ). Only studies pertaining to adults and set in the 30 EU/EEA countries (Table S6) and outside occupational settings were included in the review. No language restrictions were applied.
Two reviewers independently undertook title review, full-text review and data extraction. ECDC completed all reviews for non-English studies, with data extraction in English. Data on qualitative and quantitative outcome indicators were extracted, including information on HIV coverage, test positivity and intervention feasibility and acceptability. Two reviewers carried out quality assessment and risk of bias assignment for published studies based on National Institute for Health and Clinical Excellence (NICE) checklists and the AXIS quality assessment tool (Table S7 ). Studies were rated as being high, medium or low quality and having high, medium or low bias. Conference proceedings were not appraised for quality and bias. Critical appraisal results can be found in Table S8 .
This paper focuses on studies of HIV testing in health care settings including STI clinics, primary care, hospitals, pharmacies, prisons, drug services and TB services. HIV testing strategies involved interventions categorized as testing provision, education programmes, campaigns, use of communication technologies, use of clinical decision-making tools and other interventions. Data from HIV testing provision studies were examined for the impact of testing on HIV testing coverage. Studies documenting the feasibility and/or acceptability of HIV testing interventions studies were also included. The remaining studies covering barriers to testing, economic evaluations, audits and non-health care settings are included in the wider systematic review findings that informed the guidance (n = 238) [17] . European regions referred to are based on the United Nations geoscheme for Europe.
Results

Study identification and overview
The searches yielded 15 004 records after de-duplication; after full-text review, 368 studies were included in the overall systematic review ( Figure 1 ). Of the 368 studies, 130 are described in this paper, exploring interventions and feasibility of HIV testing in health care settings in Europe, including 84 peer-reviewed articles and 46 conference proceedings (Table S8 ) .
Studies were from 13 of the 30 EU/EEA countries. Most studies were from Northern Europe (n = 78; 64%), followed by Western (n = 23) and Southern Europe (n = 24). There was only one study from Eastern Europe [109] and four studies set across multiple European countries [110, 114, 127, 128] . The majority of the studies from Northern Europe were from the UK (92%). Other than the UK, there were two countries with more than five studies (Spain and France).
Studies were set in a range of health care facilities, the most common being primary care (n = 45) followed by inpatient services (n = 25), STI clinics (n = 24) and emergency departments (n = 23). Other health care testing sites for HIV included outpatient services (n = 16), prisons (n = 4) and pharmacies (n = 4). Almost a fifth of studies were conducted in more than one setting type.
There were a number of interventions implemented to increase HIV testing in health care settings, including innovative/improved testing provision (n = 94), use of testing campaigns (n = 14), use of communication technologies (n = 4), education and training for staff and patients (n = 20), use of tools to aid clinical decisionmaking (n = 10) and relocation of a clinic to a higher men who have sex with men (MSM) density area (n = 1). Twenty-two studies applied strategies with multiple interventions to increase testing.
The quality of the peer-reviewed studies was variable; of the 84 articles, 70% were of high quality, 19 were of medium quality (23%) and six were of low quality (7%) ( Table S8 ). Risk of bias was low in 42 studies (50%), medium in 36 studies (43%) and high in six studies (7%) ( Table S8 ).
Testing provision strategies
Novel HIV testing technologies were employed by 40 studies in a wide range of clinical settings to increase testing coverage; the majority utilized rapid testing (n = 36) [18, 19, 22, 24, 25, 34, 36, 45, 46, [48] [49] [50] 56, 57, 59, 65, 75, 77, 81, 83, 85, 88, 89, [99] [100] [101] 107, 113, 117, 129, 132, 134, 137, 139, 141] while four utilized self-sampling (n = 3) [44, 52, 102] and self-testing strategies (n = 1) [108] . Two of the four self-sampling studies used oral fluid sampling while the self-test required a blood sample. Novel testing approaches were particularly applied to improve testing coverage in HIV risk groups including MSM (n = 9) [44] [45] [46] 52, 57, 81, 85, 129, 134] , migrants (n = 7) [22, 45, 46, 57, 85, 129, 132] , and people who use/inject drugs (PWUD/ PWID) (n = 5) [50, 57, 85, 89, 129] .
Other testing strategies included routine testing (n = 32) [20, 21, 24, 25, 32, 35, 36, 43, 61, 64, 65, 69, 74, 77, 78, [92] [93] [94] [95] [96] 98, 104, 111, [115] [116] [117] 120, 125, 130, 135, 137, 147] , provision of HIV testing as a component of an integrated testing programme (n = 29) [22, 23, 32, 35, 37, 38, 47, 50, 52, 55, 62, 63, 70, 72, 74, 79, [92] [93] [94] 96, 97, 102, 103, 119, 122, 123, 134, 137, 143] , IC testing (n = 14) [26, 38, 47, 57, 88, 110, 114, 116, 120, [125] [126] [127] [128] 135] and partner notification (n = 4) [54, 60, 104, 133] . Routine testing was most commonly implemented in hospital departments including emergency departments (n = 15) [20, 21, 25, 35, 36, 64, 69, 78, 92, 93, [115] [116] [117] 137, 147] , inpatient units (n = 10) [24, 43, 61, 95, 98, 104, 111, 125, 130, 135] and outpatient departments (n = 4) [21, 74, 113, 116] . Similarly, IC testing programmes were predominantly instigated in hospitals (n = 8) [109, 114, 116, [125] [126] [127] [128] 135] and primary care (n = 10) [26, 38, 47, 57, 88, 110, 114, 116, 127, 128 ]. In contrast, integrated testing for HIV with other infections such as hepatitis B and C and STIs was adopted in diverse settings including prisons (n = 3) [70, 103, 122] , STI clinics (n = 4) [23, 52, 63, 134] , drug services (n = 2) [50, 79] and pharmacies (n = 1) [102] .
The majority of the 94 testing interventions were directed to the general population (74%). Testing strategies directed to risk groups included studies among migrants and black and minority ethnic groups (n = 12) [22, 23, 32, 45, 46, 57, 62, 80, 85, 129, 132, 143] , MSM (n = 11) [44-46, 52,57,63,81,85,129,134,136] , young people (n = 1) [102] , PWUD/PWID (n = 7) [50, 57, 79, 85, 89, 103, 129] , and mental health patients (n = 1) [123] . Often, these studies targeted multiple risk groups without presenting group-specific results. HIV test coverage and positivity differed considerably between health care settings (Table 1) . HIV test coverage varied from 2.9 to 94% in primary care and from 3.9 to 66% in emergency departments. HIV positivity ranged from 0 to 25% in STI clinics, with the higher rates achieved when partner notification was used to identify cases. In general, positivity rates were lower in studies set in emergency departments (0-1.3%) and antenatal services (0-0.05%) than in those set in other hospital departments (e.g. up to 5.3% in inpatient units).
Testing provision strategies that increase testing
Thirty studies evaluated the impact of a testing intervention by comparing the intervention data with baseline data (n = 24) [20, 26, 34, 44, 47, 65, 72, 75, 78, 80, 83, 87, 95, 96, 98, 102, 111, 113, 125, 126, 130, 133, 135, 141] or with a control group (n = 6) [22, 77, 81, 82, 120, 136] (Table 2) . Twelve studies employed novel testing (10 rapid testing and two self-sampling) in diverse settings, of which one reported an increase in HIV test coverage from 2% before the intervention to 45% after [65] , while others reported increases in HIV diagnoses [77, 141] , testing [44, 75, 83, 102] and test acceptance [81] and higher positivity rates [34] after the intervention. The use of rapid tests also resulted in 98% of people obtaining their results compared to 64% in the standard serology group [22] . One study reported a decline in numbers of tests performed [113] . A further six studies conducted in inpatient services, TB services and primary care reported the impact of IC testing: HIV test coverage changed from 3.9-72% before to 12-85% after its implementation, with most studies reporting a 10-20% increase [26, 120, 125, 126, 135] and the median number of tests also increased [47] . Twelve studies, of which half were set in inpatient services, examined the impact of universal routine testing on test coverage. These studies reported an increase in coverage from 2-28% before to 17-80% after the intervention [65, 78, 98, 111, 125, 130, 135] and higher coverage in the intervention group compared to the control group (85% versus 72%, respectively) [120] . Other indicators included increases in test acceptance [20] , numbers tested (although the increase was small) [95] and numbers diagnosed [77] and a reduction in vertical transmission [96] . Only six studies measured the impact of the intervention in at least one risk group; five in MSM [44, 81, 133, 136, 141] , one in young people [102] and one in migrants [141] .
Other HIV testing strategies targeted to providers
There were 30 studies using other strategies (campaigns, education and use of clinical decision-making tools) directed to providers. Three campaigns targeted providers to increase awareness using posters, social media (e.g. Twitter) and promotional materials [21, 111, 146] . A [48, 49] . One employed the plan, do, study, act (PDSA) methodology, which increased physicians' willingness to test but did not increase testing [84] . Another used serious incident reporting to improve testing awareness within clinics [140] . Where assessed, education provision resulted in an increase in the offer of HIV testing from 2 to 11% [146] and in the number of individuals tested from 11-13 before to 16-20 after the intervention in two smaller studies, and from 420-1056 before to 676-2333 after the intervention in two larger studies [83, 105, 112, 126] . Two studies reported a decline in test offer from 8-15% to 0-10%, which may have been attributable to the small numbers of patients included in the studies (n = 4-26) [68, 95] . There were eight studies using clinical decisionmaking tools to aid providers in identifying populations that should be tested for HIV. A variety of tools were developed: addition of HIV tests to the blood test 'set' requests or checklist [31, 39, 76, 77] , computer prompts for higher risk populations [27, 38] and risk assessments [118, 144] . Where recorded, the above interventions were successful at increasing testing [27, 31, 39] .
Other HIV testing strategies targeted to patients
Other than interventions where testing was provided, there were 23 studies using other interventions directed to patients. The majority of these interventions were campaigns that promoted local testing using social media, posters, digital media and websites [19, 78, 83, 89, 146] , campaigns to promote National HIV Testing Week [21, 71, 111, 124 ] and other regional campaigns to promote testing [48, 49, 85, 97, 142] . National HIV Testing Week increased testing from 4-9% before to 8-28% during the week [111, 124] , and it also resulted in half of those having blood samples collected at a hospital being tested for HIV [21] . During the regional Go Viral campaign, 27% of patients were tested for blood-borne viruses (BBVs) [97] . There were two educational interventions targeting patients; one for pregnant women [90] , which resulted in an increase in testing coverage (from 87 to 92%) after provision of a patient information leaflet and one for patients admitted to a hospital inpatient unit, where there was a decline in test offer (from 8 to 0%) [95] . All four communication technology studies were directed to patients, with two providing videos on HIV testing [24, 106] , one utilizing text messages to recall MSM for
Author (year) testing [136] and one using online platforms for partner notification [60] . The only study measuring intervention impact reported an increase in the re-testing rate among MSM who were actively recalled (from 19 to 44%) [136] . Two studies adopted decision-making tools that helped individuals determine if an HIV test would be recommended [42, 118] . One of these examined whether computer-assisted self-interviewing resulted in increased HIV testing when compared to interviews with clinicians [118] and found significantly less testing in the self-interviewing population (63% versus 69%, respectively). Finally, in one study, the STI clinic moved location to be in a higher MSM density area, which resulted in a large increase in the number of HIV diagnoses from 175 in 2008 to 381 in 2013 after relocation [73] .
Feasibility and acceptability
HIV testing interventions were generally acceptable to patients and providers in health care settings (Table 3) .
Results also suggest that rapid testing is acceptable to both groups (patient studies, n = 5; provider studies, n = 6), with providers willing to use rapid tests [24, 53, 56, 57, 107] and finding their interpretation easy [50] . Some feasibility studies highlighted that nontraditional health care settings can target populations not previously tested for HIV (n = 4) [18, 85, 132, 145] , with the reported percentage of first-time testers in such settings ranging from 51 to 75%.
One study suggested that provider-initiated testing is unlikely to be acceptable when specific populations are targeted (in this case, sub-Saharan African patients) [86] .
Discussion
This systematic review has identified a significant body of evidence on HIV testing in health care settings in Europe. Testing has been provided in a range of clinical settings with results suggesting that it is feasible to achieve high testing coverage, and that it is acceptable for providers and service users. HIV testing positivity ranged widely, from 0 to 25%, with higher positivity rates observed with certain strategies such as partner notification, IC testing and testing among risk groups compared to strategies that offered testing to the general population, including lower risk groups. However, the data also highlight that there is considerable room to increase the offer of testing in health care settings, particularly in primary care and emergency departments. Evidence from systematic reviews shows that, in primary care, barriers to testing are related to the clinician's knowledge [17, 148] , as well as the clinician's anxiety associated with raising the topic of HIV testing with patients [149] . Improving testing in primary care is important because in many countries more testing takes place in primary care than in specialized services, as those countries have a testing strategy that primarily uses GPs (e.g. the Netherlands and Germany) [12] . Furthermore, an evaluation of the impact of the guidance highlighted that, while over half the respondent countries reported that their national testing guidelines were closely aligned with the 2010 European guidance, only 35% included the relevant recommendations on routine offering in primary care [150] . Testing in primary care is highly acceptable to all patients, with one study among MSM also reporting primary care as an acceptable setting, and therefore interventions that increase knowledge and provide training for primary care staff could be successful at increasing test coverage. The knowledge and capability of health care staff could be enhanced through education interventions. One study in this review gave GPs training in sexual health clinical skills and achieved large increases in testing rates from 1056 tests before to 2333 after the intervention [105] , which emphasizes the impact on testing once GPs are enabled to offer testing.
In addition to testing in primary care, there are other strategies identified in this review that could improve testing coverage in health care settings in Europe, including: scaling up IC testing across all settings; introducing testing in high-prevalence areas, although the majority of studies implementing this strategy are from the UK; and implementing integrated testing for BBVs in settings such as drug services and prisons and HIV and STI testing in STI clinics. Although IC testing is an effective strategy to diagnose HIV infection and results in high positivity rates, it is not always included in national or speciality testing guidelines for specific ICs and, where it is included, the scale of implementation is quite variable [151, 152] . The concept of testing based on high diagnosed sero-prevalence areas assumes that areas of high diagnosed prevalence are likely to also have high rates of undiagnosed infections. This strategy removes the need to target specific populations, which was found to be unacceptable to primary care providers in one study in this review. The adopted strategy will, however, depend on the health care setting. Finally, integrated testing for BBVs was recently recommended in prisons by the ECDC/ European Monitoring Centre for Drugs and Drug Addiction guidance [153] .
There were only three studies set in community-based drug services and pharmacies. These venues potentially have an important role in HIV testing by reaching populations that do not necessarily attend traditional health care venues and by acting as a bridge between health care and the community. Community-based pharmacies are acceptable venues for HIV testing where testing can be implemented with basic teaching and skills provision to the pharmacist [48, 49] . Pharmacies are already an established model of delivery for chlamydia testing [154] , which only highlights the growing role of pharmacies in public health provision. Rapid testing or self-sampling kits were the adopted testing strategies in this setting. The added benefit of self-sampling kits is the possibility of providing integrated testing for BBVs and STIs [102] . The distribution of self-sampling and self-testing kits for HIV from other health care settings (e.g. STI clinics) has been found to be acceptable among MSM [44, 52] and people attending free and anonymous testing services [108] . However, further evidence is needed to understand whether this strategy can increase testing frequency in high-risk groups including MSM.
There were some limitations to this systematic review. There was only one study from Eastern Europe, which could have implications for the applicability and reproducibility of the review findings to this region. There were methodological concerns relating to measuring increases in test coverage. Although this review aimed to document the impact of intervention on increasing test coverage, a very small proportion of studies included a baseline measure or a comparator group to allow assessment of improvements in testing. Where comparisons could be made, the timeframe over which the impact of the intervention was assessed varied between studies, with most being assessed immediately after the intervention. Future studies should consider implementing interventions over longer timeframes. We restricted the review to the EU/EEA, so we may have missed studies that were applicable to and reproducible in the European setting. Finally, studies with positive findings or using novel approaches are more likely to be published. The inclusion of conference abstracts and reports (35%; 46 of 130) is therefore important to reduce publication bias; however, the quality of these studies has not been assessed. Without this assessment, we cannot know the reliability and reproducibility of the presented results. It is important that all findings including those from conference abstracts are published in peer-reviewed journals. There are three important strengths to this review. The review employed the robust PRISMA methodology which is standardized and reproducible. Secondly, the scope of the questions facilitated a broad and all-encompassing review of the literature on HIV testing in health care settings. Thirdly, the review included papers not in English, which were translated.
Conclusions
HIV testing is an integral component of combination HIV prevention, treatment and care. HIV testing is the first step in the global 90-90-90 target set by UNAIDS, where 90% of all people with HIV infection should be diagnosed, 90% of those diagnosed should receive HIV treatment and 90% of those on treatment should have a suppressed viral load by 2020 [5] . Therefore, strategies that diagnose individuals as early as possible are essential to achieve the ultimate goal of ending the HIV epidemic. This review has identified that, although there are considerable missed opportunities for earlier HIV diagnosis, there are also several acceptable and feasible strategies to achieve high HIV testing coverage across a variety of health care settings and populations in Europe.
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